🌸 Menopause Hormone Therapy Timing Hypothesis Simulator

The Vascular Estrogen-Receptivity Window

Vascular tissue loses estrogen responsiveness over time after menopause.

• 0–5 yrs: Peak receptivity (post-menopause estimate)
• ~8 yrs: Decline onset (placeholder estimate)
• high→low: Receptor density (placeholder trend)
• Endothelium: Tissue type (primary target tissue)

Receptor decline over time

Estrogen receptor density in vessel walls falls with years since onset.

Early Initiation and Cardiovascular Benefit

Initiating therapy near menopause onset associates with cardio-protection.

• <10 yrs: Benefit window (placeholder threshold)
• ↓ trend: CV risk change (placeholder direction)
• reduced: Plaque effect (placeholder finding)
• observational: Study basis (placeholder evidence type)

Mechanism of early benefit

Responsive endothelium may benefit from early estrogen exposure.

Late Initiation and Rising Risk

Starting therapy long after menopause may increase cardiovascular risk.

• >10–12 yrs: Risk threshold (placeholder threshold)
• ↑ trend: Clot risk (placeholder direction)
• destabilizing: Plaque effect (placeholder finding)
• >60 yrs: Age factor (placeholder cutoff)

Mechanism of late risk

Established atherosclerosis may respond adversely to added estrogen.

Reinterpreting Older Trial Data by Age

Age-stratified reanalysis reshapes conclusions from earlier large trials.

• mixed age: Original cohort (placeholder description)
• by decade: Reanalysis split (placeholder method)
• benefit signal: Younger subgroup (placeholder finding)
• risk signal: Older subgroup (placeholder finding)

Age-stratified reanalysis

Splitting trial cohorts by age reveals opposing timing effects.

Age and Timing-Informed Initiation Guidance

Modern guidance weighs age and years-since-onset before prescribing.

• <10 yrs: Preferred window (placeholder guidance)
• <60 yrs: Age cutoff (placeholder guidance)
• recommended: Shared decision (placeholder guidance)
• periodic: Reassessment (placeholder guidance)

Clinical decision factors

Timing, age, and individual risk jointly inform initiation choice.

Placeholder: individualized timing assessment guides therapy decisions.